April 18, 2018Open Access

Incidence, Predictors and Clinical Management of Hyperkalaemia in New Users of Mineralocorticoid Receptor Antagonists

Key Points

Key points are not available for this paper at this time.

Abstract

Among real-world adults initiating MRA therapy, hyperkalaemia was very common and frequently followed by therapy interruption, especially among participants with CKD.

Read Full Paperexternally

问 AI

Bookmark

View Full Paper

Cite This Study

Trevisan et al. (Wed,) studied this question.

synapsesocial.com/papers/69de7c1a741e97d2d4e93bb2 https://doi.org/https://doi.org/10.1002/ejhf.1199

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system2017 · 208 citations
2Relation of Serum Potassium Level to Long-Term Outcomes in Patients With Acute Myocardial Infarction2014 · 57 citations
3True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis2017 · 87 citations
4Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy2013 · 254 citations
5Associations Between Aldosterone Antagonist Therapy and Risks of Mortality and Readmission Among Patients With Heart Failure and Reduced Ejection Fraction2012 · 142 citations

问 AI

Bookmark

View Full Paper